These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 16896930)

  • 1. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
    Fury MG; Solit DB; Su YB; Rosen N; Sirotnak FM; Smith RP; Azzoli CG; Gomez JE; Miller VA; Kris MG; Pizzo BA; Henry R; Pfister DG; Rizvi NA
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):467-75. PubMed ID: 16896930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
    Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G; Soulie P; Trump D; Das-Gupta A; Small E
    Cancer; 2006 May; 106(9):1917-24. PubMed ID: 16568471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies.
    Chiorean EG; Porter JM; Foster AE; Al Omari AS; Yoder CA; Fife KL; Strother RM; Murry DJ; Yu M; Jones DR; Sweeney CJ
    Clin Cancer Res; 2008 Feb; 14(4):1131-7. PubMed ID: 18281547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA; Baker SD; Lassiter L; Sullivan RA; Dinh K; Almuete VI; Wright JJ; Donehower RC; Carducci MA; Armstrong DK
    Clin Cancer Res; 2006 Feb; 12(4):1270-5. PubMed ID: 16489083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
    Pallis AG; Christofillakis Ch; Tselepatiotis E; Agelaki S; Vamvakas L; Souglakos J; Vardakis N; Kalykaki A; Kotsakis A; Argiraki A; Mavroudis D; Georgoulias V
    Lung Cancer; 2007 Jan; 55(1):101-7. PubMed ID: 17049673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
    Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
    Miyazaki A; Kobayashi J; Yamamoto T; Kido Y; Takemura K; Abe M; Tomihara K; Dehari H; Nakamori K; Nagai I; Hiratsuka H
    Oral Oncol; 2008 May; 44(5):471-6. PubMed ID: 17826308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
    Miller VA; Johnson DH; Krug LM; Pizzo B; Tyson L; Perez W; Krozely P; Sandler A; Carbone D; Heelan RT; Kris MG; Smith R; Ochs J
    J Clin Oncol; 2003 Jun; 21(11):2094-100. PubMed ID: 12775734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
    Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
    Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
    Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Pronk LC; Schrijvers D; Schellens JH; de Bruijn EA; Planting AS; Locci-Tonelli D; Groult V; Verweij J; van Oosterom AT
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):23-8. PubMed ID: 9535208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.
    Malik SM; Collins B; Pishvaian M; Ramzi P; Marshall J; Hwang J
    Clin Lung Cancer; 2011 Jul; 12(4):231-6. PubMed ID: 21726822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
    Garland LL; Hidalgo M; Mendelson DS; Ryan DP; Arun BK; Lovalvo JL; Eiseman IA; Olson SC; Lenehan PF; Eder JP
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4274-82. PubMed ID: 16857802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
    Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
    Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
    Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
    Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
    Stinchcombe TE; Bůzková P; Choksi J; Taylor M; Bakri K; Gillenwater H; Tynan M; Mears A; Jones PE; Socinski MA
    Lung Cancer; 2006 Jun; 52(3):305-11. PubMed ID: 16638621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.